QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment

QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment

Women have higher risk for developing TdP in response to ventricular repolarization prolonging drugs. Hundreds of trials are administering chloroquine and hydroxychloroquine with/without azithromycin to COVID-19 patients. While an overall prolonged QTc has been reported in COVID-19 patients undergoi...

Full description

Bibliographic Details
Main Authors: Sarah Grewal, Lior Jankelson, Marcel P. H. van den Broek, Martin Cour, Gloria Bachmann, John B. Kostis, Kamana Misra
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
COVID
QTc changes
hydroxychloroquine
chloroquin
azithromycin (AZM)
QTc
Online Access:https://www.frontiersin.org/article/10.3389/fcvm.2020.00152/full

Internet

https://www.frontiersin.org/article/10.3389/fcvm.2020.00152/full

Similar Items